Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:21 p.m.

    📋 Surface Oncology Inc (was by Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) on 16/06/2023) (SURF) - Financial Results

    Filing Date: 2022-08-03

    Accepted: 2022-08-03 06:51:06

    Event Type: Financial Results

    Event Details:

    Surface Oncology Inc (was by Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) on 16/06/2023) (SURF) Reports the reporting period Financial Results Surface Oncology Inc (was by Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) on 16/06/2023) (SURF) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 515
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 156648
      • in to randomized Phase 2 study in first
      • line hepatocellular carcinoma (HCC) –– Cash sufficient to fund operations into 2024 –CAMBRIDGE, Mass., August 3, 2022: Surface Oncology (Nasdaq: SURF), a clinical
      • oncology company developing next
        • anticipated in 1H 2023
        • targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381
        • anticipated in the fourth quarter of 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations -18.59K -17.79K $-799.00 -4.49%
    Operating Expenses Net Loss -18.98K -19.01K $33.00 +0.17%
    Operating Expenses Net Loss Per Share -0.44 -0.44 $0.00 +0.00%
    Selected Balance Sheet Items Cash Equivalents Marketable Securities 156.65K 156.65K $0.00 +0.00%
    Loss from Operations -24.62K -18.59K $-6.04K -32.47%
    Net Loss -25.21K -18.98K $-6.23K -32.83%
    Cash and Marketable Securities 156.65K 156.65K $0.00 +0.00%
    Accounts Payable 11.21K 14.64K $-3.43K -23.44%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Surface Oncology Inc (was by Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) on 16/06/2023)
    • Ticker Symbol: SURF

Search

News categories